Kuparadzira hombe B-cell lymphoma (DLBCL) -04

VaLi, vane makore makumi matanhatu nemana (zita remanyepo), vakaonekwa vaine chirwere chakakura cheB-cell lymphoma (DLBCL) makore mana apfuura, icho chakange chafambira mberi kusvika padanho rekupedzisira rekubatanidzwa kwespleen, mbabvu, mapapu, uye pleura, inorondedzerwa sedanho IV. . Kutevera mutsara wekutanga immunochemotherapy, mamiriro ake akaramba ari mukuregererwa kweanopfuura makore matatu. Nekudaro, muna Kurume wegore rapfuura, chirwere chake chakadzokororwa, zvinosanganisira akawanda retroperitoneal lymph nodes. Pasinei nemutsara wechipiri wekununura chemotherapy, akangowana kuregererwa kwechikamu uye nekukurumidza kuderera, zvichidikanwa kurapwa kwakanyanya kudzora kuenderera mberi.

Vakatarisana nedambudziko iri rinotyisa, boka remazvikokota pachipatara cheLu Daopei rakaongorora zvakanyanya nyaya yaVaLi uye rakakoka musangano weboka remapoka akasiyana-siyana (MDT) kuti rikurudzire CAR-T cell therapy. CAR-T cell therapy, seyazvino fomu ye tumor immunotherapy, inopa zvakakosha zvakakosha sekunge kwakasimba kunanga uye kushingirira kushanda kune varwere vane kudzokazve uye refractory lymphoma.

Muna Ndira 2023, VaLi vakarapwa neCAR-T cell kuDhipatimendi reLymphoma. Asati arapwa, akaita biopsy yekurudyi inguinal lymph nodes, iyo yakasimbisa CD19 uye CD20 positivity, ichipa zvakajeka zvinangwa zveCAR-T cell therapy. Vachitungamirwa naProfessor Li, boka rekurapa rakagadzira hurongwa hwekurapa hwemunhu.

Musi waChikunguru 25, 2023, VaLi vakapedza kuisirwa kwemasero eCD19/20 CAR-T, ayo akaenderera mberi zvakanaka achitariswa nechikwata chekurapa. Pasinei nekusangana ne cytokine release syndrome, cytopenia, uye hutachiona hunokonzera mushure mekuputirwa, kutsigira kwakasimba kwekuchengetedza kwakabudirira kugadzirisa maitiro asina kunaka panguva yekurapa.

Mwedzi mitanhatu mushure mekushandisa CAR-T cell therapy, Mr. Li haana kuratidza maronda akasimba mumuviri wake wose, achiwana mhinduro yakakwana ye metabolic (CMR), iyo yakaunza tariro itsva yehutano hwake. Chikwata chekurapa chakawedzera kuwedzera maronda eretroperitoneal asara neradiotherapy kuti ive nechokwadi chekudzoka kwechirwere uye kugadzikana kwenguva refu.

Kuburikidza neCAR-T cell immunotherapy iyi, Mr. Mhosva yake inopa tariro itsva uye gwara kune varwere ve lymphoma uye inoratidza kugona uye kushanda kweCAR-T cell therapy mukurapa refractory lymphoma.

CAR-T cell therapy, senzira yekurapa kenza, iri kushandura mararamiro evarwere vane refractory lymphoma. Pasi pekunyatsotarisirwa kwechikwata chenyanzvi paDhipatimendi reLymphoma, varwere vakawanda vakaita saVaLi vanogona kutarisira kuvandudzwa kwakakosha mukupona uye hupenyu hwehupenyu. Tichitarisa kumberi, kumwe kufambira mberi uye kushandiswa kweCAR-T cell therapy kunovimbisa tarisiro yakafara uye mikana mukurapa cancer.